INSIGHTS ON CELL & GENE OUTSOURCING ISSUES

• Can CDMOs Provide Leadership In Cell And Gene Therapy?

  Learn what industry experts have to say about how CDMOs are adding value through stability and development expertise, developing partnerships with innovators, and implementing the latest technologies.

• Cell Therapy Manufacturing

  Our comprehensive package of both autologous and allogeneic cell therapy manufacturing services includes GMP production of cells from pre-clinical to commercial applications from a variety of starting materials. As an experienced cell therapy CDMO, we’re able to swiftly scale-up and support production from clinical to commercial manufacturing. Need help with the development of your cell therapy?

• Taking Your Advanced Therapy From Clinic To Commercialization

  Explore the shifts in focus for quality systems and manufacturing processes, and highlight the importance of establishing long-term supply chains, starting with the end in mind.

• Navigating The Translation To Clinic: Future-Proof Your Plasmid Products

  Future-proofing products with strategies that reduce risk and timelines for later stages can be resource-intensive but add significant value. Explore the challenges encountered progressing from development to clinic.

• A Guide To Plasmid Selection In Drug Discovery: Starting With The End In Mind

  Clinical development milestones are built on the foundations and achievements of previous phases. Explore the importance of an effective strategy, working backwards from the end-goal: commercialization.

• When Is A New Biologic Ready For GMP Production?

  While there are differences by modality in DNA, RNA, and protein, find general recommendations on questions to prepare for and steps to consider when preparing to move to clinic.

• Streamlining And Standardizing Cell And Gene Therapies From Process To Product

  Cell and gene therapies are transforming the lives of patients with various rare genetic diseases and more common conditions such as cancer. However, the rapid pace of scientific progress has overwhelmed supply infrastructure, creating pressures to scale manufacturing, increase capacity and meet a wide range of deliverable requirements.

• Why Location Matters

  While many factors can dictate the choice of a CDMO partner, the CDMO's location can have a significant influence on the communications channels, facilities, and skillsets that a potential partner has to offer.

• mRNA: How To Build A Custom Program Using CDMO Services

  Development of RNA-based therapies sits at the cutting edge of vaccine and oncology innovation, in addition to holding promise in dozens of other therapeutic areas.

• Reducing Adverse Events And Improving Outcomes During And After Cell and Gene Therapy

  As concerns involving the use of DMSO as a cryoprotectant grow, researchers and contract development and manufacturing organizations (CDMOs) have begun pursuing non-toxic and process-friendly alternatives.